OssDsign AB
STO:OSSD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6
10.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OssDsign AB
Cash & Cash Equivalents
OssDsign AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OssDsign AB
STO:OSSD
|
Cash & Cash Equivalents
kr165.9m
|
CAGR 3-Years
50%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Cash & Cash Equivalents
kr450m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Cash & Cash Equivalents
kr11.8m
|
CAGR 3-Years
121%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cash & Cash Equivalents
kr123.2m
|
CAGR 3-Years
132%
|
CAGR 5-Years
131%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Cash & Cash Equivalents
€39.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cash & Cash Equivalents
kr1.4m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
OssDsign AB
Glance View
OssDsign AB is a holding company, which designs, manufactures, and sells implants and material technology for bone regeneration. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2019-05-24. The company aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The firm uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The firm's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
See Also
What is OssDsign AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
165.9m
SEK
Based on the financial report for Dec 31, 2023, OssDsign AB's Cash & Cash Equivalents amounts to 165.9m SEK.
What is OssDsign AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
64%
Over the last year, the Cash & Cash Equivalents growth was 33%. The average annual Cash & Cash Equivalents growth rates for OssDsign AB have been 50% over the past three years , 64% over the past five years .
You don't have any saved screeners yet
